Rezolute

Executive Director, Payer Strategy and Engagement (Tumor HI Program)

Redwood City · Director

Sponsorship not specified$290k-$320kDetected 50 days ago

SalesExcelICD-10ResearchLeadershipCommunicationCollaborationMicrosoft OfficeEpidemiology

About the role

Provide critical leadership and above-country market access strategies including core disease models, value stories, global pricing, economic modeling, and input into Clinical Development programs.
Work closely with Medical Affairs colleagues, Organized customers and Distribution providers to identify real-world and patient quality of life data capture / evidence value solutions and publication opportunities.
Understands total cost of care and all aspects of reimbursement (coverage, coding, and payment) for outpatient and inpatient settings across multiple payer segments.

Engage to support the advancement of ICD-10 CM coding initiatives, and product-specific HCPCS coding application.
Support the identification, creation of defensible, performance driven, quality / outcomes or risked based product / portfolio contract, or rebate opportunities.
Manage/recruit in-house or contracted payer account team to educate key payers using PIE (Payer Information Exchange) before approval and PVP (Payer Value Proposal) after the approval
Educate payers on the label and influence them to develop policies based on the label and/or clinical trial exclusion criteria
Resolve rejection/prior authorization issues by closely working with the payers and patients support services team and hub in a timely manner

Familiarity with current legal and regulatory landscape pertinent to the pharmaceutical/biotechnology industry.
Experience with rare/orphan drugs is required. Therapeutic area experience is a plus.
Strong analytical capabilities, with working knowledge of government pricing practices (calculations methodologies, HTA, healthcare programs, and supporting regulations), and trade systems and processes.
Demonstrated flexibility to adapt to a changing environment, implement creative solutions to complex problems, and ability to function in a project leadership role.
Ability to develop and maintain strong internal and external relationships, including direct collaboration with vendors and other third parties.
Superior interpersonal, oral and written communication, and presentation skills, with great attention to detail.
Leads with strong business acumen and a compliance mindset.
Passionate about patients and building a new commercial organization.
Advanced Microsoft Excel, Word and PowerPoint skills.

Therapeutic area experience is a plus.
Product launch experience is required, and company start-up experience is preferred.
Minimum Bachelor's degree required
Experience with rare/orphan drugs is required.

Rezolute (RZLT) currently anticipates the base salary for the Executive Director, Payer Strategy and Engagement role could range from $ 290,000 to $320,000 and will depend, in part, on the successful candidate's geographical location and th

Minimum Bachelor's degree required; sciences or business preferred, advanced degree related medical, health economics, health outcomes research, or epidemiology (MS, MBA, MPH, MD/DO, PhD, PharmD) preferred.
5 years of US market access and reimbursement experience required, with Global and/or international experience preferred.
This includes, HTA, US Payer, Patient and Provider access, HEOR, and medical benefit reimbursement coding expertise.
Health Insurance (Medical / Dental / Vision)
Disability, Life & Long-Term Care Insurance
Tracking Free Vacation Program
Educational Assistance Benefit
Fitness Center Reimbursement
Identify and develop pricing recommendations, coding and reimbursement strategies for current and pipeline assets that will support future Pricing and Reimbursement decisions in the US and other key Ex-US markets.
Identify pricing and reimbursement analogues to support value and access decisions.

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders.
Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.
Rezolute's lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI).
As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

This listing is sourced directly from Rezolute's careers page and normalized into a canonical job model.